Revenue for companies that have reported 2Q to date is presented below. Exhibit 1 displays orthopaedic sales growth by product segment for the quarter, and performance highlights follow.

Exhibit 1 displays orthopaedic sales growth by product segment for the quarter, and performance highlights follow.

Biomet (FY2013 ended 5/31/13; reporting is preliminary)
$3,052.9MM, +9% (U.S. $1,862.2MM, +9%; Europe $710.2MM, +5%; International $480.5MM, +19%)

Reconstructive $1,696.3MM, +2%

• Hips +2%
• Knees +1%
• Bone Cement/Other +2%

Sports/Extremities Trauma $600.1MM, +68%

• SportsMed +8%
• Extremities +20%
• Trauma +259%

Spine/Bone Healing $291.3MM, -5%

• Spine +1%
• Bone Healing -21%

Dental $257.0MM, -2%

Other $208.2MM, +4%

• Divested bracing business to Breg in February 2013
• FY2014 launches include patient-specific tibial trays and posterior-stabilized thermal components, new Soft Anchor midway through fiscal year, expansion to ACL portfolio, bone-conserving comprehensive Nano shoulder in Europe

FY4Q13 revenue:
$783.9MM, +8% (U.S. $466.3MM, +6%; Europe $188.7MM, +5%; International $128.9MM, +17%)

Reconstructive $435.2MM, +1% (U.S. +1%)

• Hips +2% (U.S. +2%)
• Knees +0.1% (U.S. +0.1%)
• Bone Cement/Other -1% (U.S. -3%)

Sports/Extremities Trauma $159.2MM, +65% (U.S. +56%)

• SportsMed +1% (U.S. -4%)
• Extremities +22% (U.S. +28%)
• Trauma +267% (U.S. +249%)

Spine/Bone Healing $67MM, -18% (U.S. -19%)

• Spine -8% (U.S. -8%)
• Bone Healing -48% (U.S. -48%)

Dental $68.5MM, +0.2% (U.S. +2%)

Other $54MM, +7% (U.S. +2%)

Recon

• Double-digit combined hip/knee growth in both Japan and China
• Worldwide hip/knee pricing declined in lowsingle-digits
• Continued rollout of Taperloc Complete hips, including full-length and microplasty short stem,
• plus XR 123 option featuring same stem geometry with 123-degree neck angle and shorter neck
• Commenced limited ex-U.S. launch for Sirius double-tapered short hip stem for primary/revision
• ~450 G7 next-gen multi-bearing acetabular cup procedures complete, to date
• Launched SSK 360 in Japan, as well as Vanguard Select patient-specific femur
• Noted increased market penetration for Signature total and partial knees and Orthosize digital x-ray templating software
• Slight decline in global partial knees
• Initiated U.S. direct-to-consumer T.V. ad supporting Oxford Partial Knee’s lifetime warranty

Cement/Other

• Strong EMEA market demand for Optipac prefilled cement mixing system
• Received Japan regulatory approval for Cobalt cement, 1st entry into bone cement market there

Extremities

• Extremities driven by comprehensive shoulder (includes primary, reverse, fracture and segmental revision options)
• Initiated global launch of Access instrumentation for glenoid preparation, releasing 150 sets, with 100 additional slated for each month during 1HFY14

Trauma

• Launched DVR Crosslock ePAK delivery system

Spine

• Hardware impacted by mid-single-digit price decline
• Introduced Translation pedicle screw with Polaris 5.5 Thoracolumbar spine system via limited clinical release

(Growth includes trauma acquisition and bracing divestiture)
Biomet has not yet filed its 10-Q.

ConMed
Orthopaedic surgery product sales $101.8MM, -1%

• Sports Medicine -3% (Sports Biologics +4%)
• Powered Surgical -1%
• Sports Med affected by foreign currency effects, government-imposed limits on procedures/ spending in Europe (especially the U.K.), discontinued line of craniofacial devices (posted <$1MM in 2Q12, none in 2Q13)
• Lithium ion battery, launched at AAOS, performing extremely well; can take market share in Europe
• Note: Surgical visualization products previously included under Arthroscopy category are broken out separately, as video systems can be used in both general and orthopaedic surgery

DJO Global
$294.7MM, +3%

• Bracing/Vascular $119.4MM, +5%
• Recovery Sciences $77.2MM, -8%
• International $76.8MM, +8%
• Surgical Implant $21.4MM, +18%

(Bracing and Vascular includes products serving the diabetes market.)

• Bracing/Vascular buoyed by new products, including Aircast AirSelect walking boot
• Recovery Sciences still impacted by 2012 Medicare non-coverage decision on Transcutaneous Electrical Nerve Stimulation for low back pain, slow market for capital equipment purchase
• Surgical Implant driven by shoulder arthroplasty, which grew 25%+; hip and knee growing ahead of market
• Noting significant growth headwinds in joint reconstruction sector
• In 3Q, launched Empi Phoenix muscle stimulator for total knee and ACL recovery, addresses muscle atrophy